美國

證券交易委員會
華盛頓特區20549

13D附表
(規則 13D - 101)

根據13d-1(a)提交的報表中應包括的信息和
根據13d-2(a)提交的修改

（第五次修訂）*

Tango Therapeutics, Inc.

---

（發行人名稱）

普通股，每股面值爲$0.001

---

（證券種類名稱）

87583X109

---

（CUSIP編號）

Josh La Grange

弗裏德，弗蘭克，賀錦麗，施裏弗和詹博森律師事務所

801 17th Street, NW, Washington, DC 20006

如果申報人此前已在表格13G上報告本表13D的對象所涉及的獲取情況，並且 因爲規則13d-l（e）、13d-l（f）或13d-l（g）的緣故而報告此表格，請打勾此框☐。
George A. Stephanakis

2024年10月25日

---

（要求提交此聲明的事件日期）

如果申報人已經在表格13G中提交了一份報告，以報告本表格13D的收購，且是由於§§240.13d-1(e)、240.13d-1(f) 或240.13d-1(g)而提交此表格，請勾選下面的框 ☐.

單張債券以紙質形式提交的日程安排應包括一份簽署的原件和五份日程安排，包括所有附件。 有關應將副本寄送給其他方的信息，請參見§240.13d-7。

* 本封面的其餘部分應填寫爲報告人關於本表格涉及的證券主體類別的首次申報，以及包含可能改變先前封面提供的披露信息的任何後續修正。

剩餘部分的信息應不被視爲本法案第18條的目的「已提交」，或者對該法案的其他部分承擔責任，而是應對該法案的所有其他規定承擔責任（但請參見 備註）。

CUSIP編號 87583X109

1	報告人的名稱
	BCTG控股有限責任公司
2	如果是一組的成員，請檢查適當的框（見說明書）			(a)	☐
				(b)	☒
3	僅供SEC使用
4	資金來源（請參見說明）
	無數據
5	如果按照2(D)或2(E)項規定需要披露法律訴訟，請複選框				☐
6	公民身份或組織地點
	特拉華州
每個報告人擁有的受益股數爲		7	唯一擁有投票權的股份數量
			6,988,450
		8	具有共同投票權
			0
		9	具有唯一處理權
			6,988,450
		10	具有共同處理權
			0
11	每位報告人受益擁有的合計數量
	6,988,450
12	若在第（11）列的合計金額不包括某些股份（請參閱說明），請勾選複選框。				☐
13	第（11）列金額所代表的類別所佔的百分比。
	6.5%
14	報告人類型（請參閱說明）。
	OO

With respect to Boxer Capital Management, LLC (“BCM”), BCTG Holdings, LLC (“BCTG Holdings”), MVA Investors, LLC (“MVA Investors”) and Aaron I. Davis (together with BCM, BCTG Holdings and MVA Investors, the “Reporting Persons”), this amendment (this “Amendment No. 5”) further amends and supplements the statement on Schedule 13D filed on August 20, 2021 (the “Original Filing”) by BCTG Holdings, MVA Investors, Mr. Davis and certain other persons with respect to the Common Stock, par value $0.001 (the “Common Stock”) of Tango Therapeutics, Inc. (the “Issuer”), as previously amended and filed on January 4, 2022 (“Amendment No. 1”), August 16, 2023 (“Amendment No. 2”), October 18, 2023 (“Amendment No. 3”) and October 15, 2024 (“Amendment No. 4”). In Amendment No. 4, BCM adopted the Original Filing as previously and then amended as its statement on Schedule 13D with respect to the Common Stock. Capitalized terms used herein but not defined herein shall have the respective meanings defined in the Original Filing, as previously amended. The Original Filing, as previously amended, is further amended hereby only as specifically set forth herein, provided that with respect to any Item amended herein, if such Item is incorporated by reference into any other Item in the Original Filing, as previously amended, such incorporation by reference is also amended hereby.

Item 2 is hereby amended to correct that Mr. Davis is the Managing Member of BCM.

Items 5(a) and (b) are hereby amended and restated to read as follows:

(a) (b) For information regarding beneficial ownership, see the information presented on the cover pages. All percentages are based on 107,176,965 shares of the Issuer’s Common Stock outstanding, which is (i) 107,144,465 shares of the Issuer’s Common Stock outstanding as of August 1, 2024 as set forth in the Issuer’s 10-Q filed with the Securities and Exchange Commission on August 7, 2024, plus (ii) 32,500 shares of Common Stock subject to options to purchase shares of Common Stock, held by Mr. Davis, exercisable in the next 60 days.

Item 5(c) is hereby supplemented by the addition of the following:

BCM caused an account under its management to sell shares of the Issuer’s Common Stock in the open market for cash on October 21, 2024, October 22, 2024 and October 25, 2024, in each case in the number and at the average price disclosed in a filing on Form 4.

Item 7 is hereby amended by the addition of the following:

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated:  October 28, 2024